Natalizumab: An antibody targeting α4-Integrin

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS), in which inflammation develops upon leukocyte invasion into the CNS via the blood-brain barrier. α4-Integrin is an important cell adhesion molecule involved in the penetration process. Natalizumab is an α4-integrin-targeting monoclonal antibody that was recently approved for use as a disease-modifying therapy for MS in Japan. In this article, the mechanism of action, efficacy, and side effects of natalizumab will be reviewed.

Original languageEnglish
Pages (from-to)1149-1158
Number of pages10
JournalBrain and Nerve
Issue number10
Publication statusPublished - 2014 Oct 1


  • Blood-brain barrier
  • Multiple sclerosis
  • Natalizumab
  • Progressive multifocal leukoencephalopathy
  • α 4-integrin

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Natalizumab: An antibody targeting α4-Integrin'. Together they form a unique fingerprint.

Cite this